Granted Patent
B2
US 12,312,593 · App. 18/375,868 · Granted May 27, 2025
Lymphocyte targeted lentiviral vectors
Assignee:
Kelonia Therapeutics, Inc.
C12N15/86A61K40/10A61K40/11A61K40/31A61K40/4211A61K40/4215C07K14/005C07K14/70532C07K16/2803C07K16/2809C07K16/2878A61K2239/31A61K2239/48C07K2317/622C07K2319/03C12N2740/15022C12N2740/15043C12N2740/15051C12N2760/20222
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the present disclosure.
Claims (10)
1. A polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 90, wherein the polypeptide comprises an amino acid substitution at position 182.
2. The polypeptide of claim 1 , further comprising an amino acid substitution at position 352.
3. The polypeptide of claim 2 , wherein the amino acid substitution at position 352 is from threonine to an amino acid selected from the group consisting of: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, tryptophan, tyrosine, and valine.
4. The polypeptide of claim 1 , wherein the amino acid substitution at position 182 is from isoleucine to an amino acid selected from the group consisting of: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
5. The polypeptide of claim 4 , further comprising an amino acid substitution at position 352.
6. The polypeptide of claim 5 , wherein the amino acid substitution at position 352 is from threonine to an amino acid selected from the group consisting of: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, tryptophan, tyrosine, and valine.
7. A nucleic acid encoding the polypeptide of claim 1 .
8. A lentiviral vector comprising an envelope comprising the polypeptide of claim 1 .
9. The lentiviral vector of claim 8 , wherein the envelope further comprises a heterologous lymphocyte targeting protein comprising an extracellular domain comprising a lymphocyte targeting domain and a transmembrane domain.
10. The lentiviral vector of claim 9 , further comprising an expression cassette that comprises a heterologous transgene encoding a chimeric antigen receptor.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 3, 2024
From: PERKINS, MOLLY R.; FRIEDMAN, KEVIN M.
To: KELONIA THERAPEUTICS, INC.
Reel/Frame 066998/0440 →
Continuity (3)
Continuation
18279201
Provisional Application
63154639
· Feb 26, 2021
References Cited (105)
US 7901671B2
· Leboulch et al.
· 2011
[cited by applicant]
US 9994867B2
· Baltimore et al.
· 2018
[cited by applicant]
US 20150182617A1
· Bauche et al.
· 2015
[cited by applicant]
US 20170176435A1
· Seidell, III et al.
· 2017
[cited by applicant]
US 20220204946A1
· Antunes et al.
· 2022
[cited by applicant]
US 20220340876A1
· Birnbaum et al.
· 2022
[cited by applicant]
US 20240218390A1
· Perkins et al.
· 2024
[cited by applicant]
CA 2344208A1
· 2002
[cited by applicant]
CN 108040484A
· 2018
[cited by applicant]
WO 200119380A2
· 2001
[cited by applicant]
WO 2008037458A2
· 2008
[cited by applicant]
WO 2009013324A1
· 2009
[cited by applicant]
WO 2012088381A2
· 2012
[cited by applicant]
WO 2015104376A1
· 2015
[cited by applicant]
WO 2015112541A2
· 2015
[cited by applicant]
WO 2015117027A1
· 2015
[cited by applicant]
WO 2017182585A1
· 2017
[cited by applicant]
WO 2019056015A2
· 2019
[cited by applicant]
WO 2019057974A1
· 2019
[cited by applicant]
WO 2020123936A1
· 2020
[cited by applicant]
WO 2020236263A1
· 2020
[cited by applicant]
WO 2022183072A1
· 2022
[cited by applicant]
WO 2022221745A1
· 2022
[cited by applicant]
Zhang, N., et al., “Leucine-rich Repeat-containing G Protein-coupled Receptor 4 Facilitates Vesicular Stomatitis Virus Infection by Binding Vesicular Stomatitis Virus Glycoprotein,” J Biol Chem, 292(40):16527-16538 (201…
[cited by applicant]
Bowie, J., et al., “Deciphering the Message in Progein Sequences: Tolerance to Amino Acid Substitutions,” Science, 247(4948):1306-10 (1990).
[cited by applicant]
Winkler, K., et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody,” J Immunol, 165(8):4505-14 (2000).
[cited by applicant]
Kussie, P., et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” J Immunol, 152(1):146-52. (1994).
[cited by applicant]
Chen, Z., et al., “Human Monoclonal Antibodies Targeting the Haemagglutinin Glycoprotein can Neutralize H7N9 Influenza Virus,” Nat Commun, 6:6714 (2015).
[cited by applicant]
Sela-Culang, I., et al., “The Structural Basis of Antibody-Antigen Recognition,” Front Immunol, 4:302 (2013).
[cited by applicant]
Sirin, S., et al., “AB-Bind: Antibody Binding Mutational Database for Computational Affinity Predictions,” Protein Sci, 25(2):393-409 (2015).
[cited by applicant]
Höfig, I., et al., “Systematic Improvement of Lentivirus Transduction Protocols by Antibody Fragments Fused to VSV-G as Envelope Glycoprotein,” Biomaterials, 35(13):4204-12 (2014).
[cited by applicant]
Dreja, H., et al., “The Effects of N-terminal Insertion into VSV-G of an scFv Peptide,” Viral J, 3:69, 1186 (2006).
[cited by applicant]
Kameyama, Y., et al., “Antibody-dependent Gene Transduction using Gammaretroviral and Lentiviral Vectors Pseudotyped with Chimeric Vesicular Stomatitis Virus Glycoprotein,” J Viral Methods, 153(1 ):49-54 (2008).
[cited by applicant]
Yu, B., et al., “Engineered Cell Entry Links Receptor Biology with Single-cell Genomics,” Cell, 185(26):4904-4920 (2022).
[cited by applicant]
Nikolic, J., et al., “Structural Basis for the Recognition of LDL-receptor Family Members by VSV Glycoprotein,” Nat Commun, 9(1):1029 (2018).
[cited by applicant]
Yang, H., et al., “Cell Type-Specific Targeting with Surface-Engineered Lentiviral Vectors Co-displaying OKT3 Antibody and Fusogenic Molecule,” Pharm Res, 26(6): 1432-45 (2009).
[cited by applicant]
Frank, A., et al., “Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes,” Mol Ther Methods Clin Dev, 12:19-31 (2018).
[cited by applicant]
Milani, M., et al., “Genome Editing for Scalable Production of Alloantigen-free Lentiviral Vectors for in vivo Gene Therapy,” EMBO Mol Med, 9(11):1558-1573 (2017).
[cited by applicant]
Goyvaerts, C., et al., “Development of the Nanobody Display Tecnology to Target Lentiviral Vectors to Antigen-Presenting Cells,” Gene Therapy, 19:1133-1140 (2012).
[cited by applicant]
Chan, L., et al., “Conjugation of Lentivirus to Paramagnetic Particles via Nonviral Proteins Allows Efficient Concentration and Infection of Primary Acute Myeloid Leukemia Cells,” J. of Virology, 79(20):13190-13194 (200…
[cited by applicant]
Ammayappan, et al., “Characteristics of Oncolytic Vesicular Stomatitis Virus Displaying Tumor-Targeting Ligands,” Journal of Virology vol. 87(24):13543-13555 (2013).
[cited by applicant]
Altschul, et al., “Basic Local Alignment Search Tool,” J Mol Biol. (3):403-10 (1990).
[cited by applicant]
Altschul, et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,” Nucleic Acids Res, 25(17):3389-402 (1997).
[cited by applicant]
Bentzen, et al., “Evolution of MHC-based Technologies Used for Detection of Antigen-responsive T Cells,” Cancer Immunol Immunother, 66:657-66 (2017).
[cited by applicant]
Buchholz, et al., “Retroviral Display and High Throughput Screening,” Comb Chem High Throughput Screen, 11(2):99-110 (2008).
[cited by applicant]
Cire, S, “Immunization of Mice with Lentiviral Vectors Targeted to MHC Class II+ Cells is Due to Preferential Transduction of Dendritic Cells in vivo,” PLoS One, 9(7):e101644, (2014).
[cited by applicant]
Dobson, C., et al., “Antigen Identification and High-Throughput Interaction Mapping by Reprogramming Viral Entry,” Nature Methods, 19:449-460 (2022).
[cited by applicant]
Finkelshtein, et al., “LDL Receptor and its Family Members Serve as the Cellular Receptors for Vesicular Stomatitis Virus,” PNAS, 110(18):7306-7311 (2013).
[cited by applicant]
Frank, AM, “Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes,” Mol Ther Methods Clin Dev, 12:19-31, (2018).
[cited by applicant]
Froelich, et al., “Targeted Gene Delivery to CD117-expressing Cells in vivo with Lentiviral Vectors Co-displaying Stem Cell Factor and a Fusogenic Molecule,”, Biotechnology and Bioengineering, 104(1):206-215 (2009).
[cited by applicant]
Funke, et al., Targeted Cell Entry of Lentiviral Vectors,: Mol Ther. I6(8):1427-36 (2008).
[cited by applicant]
Grubaugh, et al., “Proteins as T Cell Antigens: Methods for High-throughput Identification,” Vaccine 31(37) (2013).
[cited by applicant]
Guideng, et al., “T Cell Antigen Discovery Via Trogocytosis,” Nature Methods, 16(2):183-90 (2019).
[cited by applicant]
Hastie, E, et al., “Understanding and Altering Cell Tropism of Vesicular Stomatitis Virus,” Virus Res. 176(1-2):16-32 (2013).
[cited by applicant]
He, et al., “Can Immunotherapy Reinforce Chemotherapy Efficacy? A New Perspective on Colorectal Cancer Treatment,” Front. Immunol. 14:1237764 (2023).
[cited by applicant]
Joglekar, et al., “T Cell Antigen Discovery via Signaling and Antigen-presenting Bifunctional Receptors,” Nature Methods, 16(2):191-8 (2019).
[cited by applicant]
Karlin, et al., “Applications and Statistics for Multiple High-scoring Segments in Molecular Sequences,” Proc Natl Acad Sci US A, 90(12):5873-7 (1993).
[cited by applicant]
Karlin, et al., “Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes,” Proc Natl Acad Sci US A., 87(6):2264-8 (1998).
[cited by applicant]
Labbe, R., et al., “Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives,” Viruses 13(1528): 1-22 (2021).
[cited by applicant]
Nikolic, J., et al., “Structural Basis for the Recognition of LDL-Receptor Family Members by VSV Glycoprotein,” Nature Communications, 9(1029):1-12 (2018).
[cited by applicant]
Ou, W, et al., “Specific Targeting of Human Interleukin ( I L)-13 Receptor A2-positive Cells with Lentiviral Vectors Dsplaying I L-13,” Hum Gene Ther Methods, 2:137-47, (2012).
[cited by applicant]
Peach, et al., “Both Extracellular Immunoglobin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28, ”J. Biol Chem, 270(36):21181-21187 (1995).
[cited by applicant]
Sevier, CS, et al., “Efficient Export of the Vesicular Stomatitis Virus G Protein from the Endoplasmic Reticulum Requires a Signal in the Cytoplasmic Tail that Includes both Tyrosine-based and Di-acidic Motifs,” Mol Bio…
[cited by applicant]
Taube, et al., “Lentivirus Display: Stable Expression of Human Antibodies on the Surface of Human Cells and Virus Particles,” PLoS One, 3(9):e3181 (2008).
[cited by applicant]
Urban, et al., “Retroviral Display in Gene Therapy, Protein Engineering, and Vvaccine Development,” ACS Chem Biol., 6(1):61-74(2011).
[cited by applicant]
Urban, et al., “Selection of Functional Human Antibodies from Retroviral Display Libraries,” Nucleic Acids Res., 33(4):e35 (2005).
[cited by applicant]
Yang, et al., “Cell Type-specific Targeting with Surface-engineered Lentiviral Vectors Co-displaying OKT3 Antibody and Fusogenic Molecule,” Pharm Res. (6):1432-45 (2009).
[cited by applicant]
Yang, et al., “Targeting Lentiviral Vectors to Specific Cell Types in vivo,” PNAS, 103(31 ):114 79-84 (2006).
[cited by applicant]
Zhang, et al., “Cell-specific Targeting of Lentiviral Vectors Mediated by Fusion Proteins Derived from Sindbis Virus, Vesicular Stomatitis Virus, or Avian Sarcoma/Leukosis Virus,” Retrovirology, Biomed Central Ltd., 7(1…
[cited by applicant]
International Search Report from International Application No. PCT/US2022/018027, dated mailed: Jun. 21, 2022.
[cited by applicant]
International Search Report from International Application No. PCT/US2020/024175, date mailed: Sep. 14, 2020.
[cited by applicant]
International Search Report from International Application No. PCT/US2022/025142, dated: Apr. 10, 2022.
[cited by applicant]
International Search Report from International Application No. PCT/EP2018/075824, dated: Nov. 28, 2018.
[cited by applicant]
Petition for Post-Grant Review of U.S. Pat. No. 11,767,366, Before the Patent Trial and Appeal Board,
[cited by applicant]
Patent Owner's Preliminary Response with Exhibit 2001, in U.S. Pat. No. 11,767,366, Before the Patent Trial and Appeal Board,
[cited by applicant]
Petitioner's Reply to Patent Owner's Preliminary Response in U.S. Pat. No. 11,767,366, Before the Patent Trial and Appeal Board,
[cited by applicant]
Patent Owner's Sur-Reply in U.S. Pat. No. 11,767,366, Before the Patent Trial and Appeal Board,
[cited by applicant]
Abertini, et al., “Molecular and Cellular Aspects of Rhabdovirus Entry,” Viruses, 4:117-139 (2012).
[cited by applicant]
Amirache, et al., “Mystery Solved: VSV-G-LVs Do Not Allow Efficient Gene Transfer into Unstimulated T Cells, B Cells, and HSCs Because They Lack the LDL Receptor,” Blood, 123: 1422-1424 (2014).
[cited by applicant]
Barber, G.N., “VSV-tumor Selective Replication and Protein Translation,” Oncogene 24: 7710-7719 (2005).
[cited by applicant]
Ferlin, et al., “Characterization of pH-sensitive Molecular Switches that Trigger the Structural Transition of Vesicular Stomatitis Virus Glycoprotein from the Postfusion State Toward the Prefusion State,” J Virol, 88:1…
[cited by applicant]
Roche, et al., “Crystal Structure of the Low-pH Form of the Vesicular Stomatitis Virus Glycoprotein,” G. Science, 313: 187-191 (2006).
[cited by applicant]
Roche, et al., “Structure of the Prefusion Form of the Vesicular Stomatitis Virus Glycoprotein G,” Science 315: 843-848 (2007).
[cited by applicant]
An, X., “Preliminary Study on HBV and HIV seudovirus Vector Systems,” China Master's Thesis Full-text Database, Basic Science Collection: 1-121 (2007).
[cited by applicant]
Cited By (3)